Pharmaron Beijing Co Ltd
HKEX:3759

Watchlist Manager
Pharmaron Beijing Co Ltd Logo
Pharmaron Beijing Co Ltd
HKEX:3759
Watchlist
Price: 19.26 HKD -5.68% Market Closed
Market Cap: HK$55.1B

Pharmaron Beijing Co Ltd
Investor Relations

Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys.

The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.

Show more
Loading
3759
Hang Seng (Hong Kong)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Boliang Lou Ph.D.
Chairman & CEO
No Bio Available
Mr. Xiaoqiang Lou EMBA
Co-Founder, President, COO & Executive Director
No Bio Available
Ms. Bei Zheng M.A, M.A.
Executive VP & Executive Director
No Bio Available
Mr. Shing Chung Li C.F.A., CPA
CFO & Secretary of the Board
No Bio Available
Dr. Hua Yang Ph.D.
Chief Scientific Officer & Deputy Manager
No Bio Available
Dr. Connie Sun Ph.D.
Senior VP & Global Head of Business Development of Small Molecules
No Bio Available
Ms. Celina Zhong M.B.A., MBA
Senior Vice President of Human Resources
No Bio Available
Ms. Katherine Lee M.B.A., MBA
Chief Business Officer
No Bio Available
Mr. Stephen Lewinton
Senior Vice President of UK Operations
No Bio Available
Dr. Jingqi Huang
Senior Vice President of In Vivo Pharmacology
No Bio Available

Contacts

Address
BEIJING
Beijing
No. 6 Taihe Road, Beijing Economic and Technological Development Zone
Contacts
+861057330087.0
www.pharmaron.cn
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett